Clinical Trials Logo

Primary Sclerosing Cholangitis clinical trials

View clinical trials related to Primary Sclerosing Cholangitis.

Filter by:

NCT ID: NCT00325013 Completed - Clinical trials for Primary Sclerosing Cholangitis

Evaluation of DHA for the Treatment of PSC

Start date: December 2005
Phase: Phase 1
Study type: Interventional

The researches aim to study the effects of DHA (component of fish oil) on patients with Primary Sclerosing Cholangitis (PSC). Our hypothesis is that DHA might reverse the problems associated with PSC.

NCT ID: NCT00179439 Completed - Clinical trials for Inflammatory Bowel Disease

NPDT Evaluation in Children With CFTR and (PSC)

NPD
Start date: January 2004
Phase: N/A
Study type: Observational

The investigators hypothesize that PSC in children is associated with mutations and functional changes of the cystic fibrosis (CF) gene.

NCT ID: NCT00161148 Recruiting - Clinical trials for Primary Sclerosing Cholangitis

Probiotics in Patients With Primary Sclerosing Cholangitis

Start date: January 2005
Phase: Phase 3
Study type: Interventional

PSC is a progressive liver disease without effective medical treatment. There is often co-existent ulcerative colitis. Probiotics (bacterial food supplements) have been shown to benefit patients with ulcerative colitis. In the current protocol potential beneficial effects of probiotics on liver biochemistry and liver related symptoms as pruritus are being assessed in 12 PSC patients in a randomized controlled cross over study (3 months probiotics, 1 one wash-out and 3 months placebo).

NCT ID: NCT00059202 Terminated - Clinical trials for Primary Sclerosing Cholangitis

Trial of High-dose Urso in Primary Sclerosing Cholangitis

Start date: July 2002
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multicenter, randomized, controlled trial of high dose ursodiol versus placebo for patients with primary sclerosing cholangitis (PSC). The average duration of follow-up will be approximately five years with important clinical endpoints such as death, eligibility for liver transplantation, changes in histology and cholangiogram as well as liver biochemistries and quality of life data collected.